Merdrignac, LoreLaniece Delaunay, CharlotteVerdasca, NunoVega‐Piris, LorenaO'Donnell, JoanSève, NoémieTrobajo‐Sanmartín, CaminoBuda, SilkeHooiveld, MariëtteRodrigues, Ana PaulaTúri, GergőLatorre‐Margalef, NeusMlinarić, IvanLazar, MihaelaMaurel, MarineCastrillejo, DanielBennett, CharleneRameix‐Welti, Marie‐AnneMartínez‐Baz, IvánDürrwald, RalfMeijer, AdamMelo, AryseOroszi, BeatrixHagey, Tove SamuelssonKurečić Filipović, SanjaDijkstra, FrederikaGómez, VerónicaBacci, SabrinaKaczmarek, MarlenaKissling, EstherVEBIS Primary Care Vaccine Effectiveness Group2025-03-112025-03-112024-11-10Influenza Other Respir Viruses . 2024 Nov;18(11):e70009. doi: 10.1111/irv.70009http://hdl.handle.net/10400.18/10432Mapear com DDIWe estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection among adults aged ≥65 years during the 2023/2024 JN.1 lineage-predominant period in a European multi-country test-negative case–control study at primary care level. We estimated VE adjusted by study site, age, sex, chronic conditions and onset date. We included 220 cases and 1733 controls. The VE was 48% (95% CI: 12–71), 23% (95% CI: −11–48) and 5% (95% CI: −92–56) among those with symptom onset 1–5, 6–11, and ≥12weeks after vaccination, respectively. XBB.1.5 vaccine provided short and moderate protection against JN.1 symptomatic infection.engCOVID-19SARS-CoV-2Case–control StudyTest-negative DesignVaccine EffectivenessPrimary CareMulti-country StudyInvestigação em Serviços de Saúdejournal article10.1111/irv.70009